Synopsis
Synopsis
0
CEP/COS
0
JDMF
0
EU WC
0
KDMF
0
NDC API
0
VMF
0
EDQM
0
USP
0
JP
0
Others
0
FDF Dossiers
0
FDA Orange Book
0
Europe
0
Canada
0
Australia
0
South Africa
0
Listed Dossiers
DRUG PRODUCT COMPOSITIONS
0
US Patents
0
US Exclusivities
0
Health Canada Patents
US Medicaid
NA
Annual Reports
NA
Regulatory FDF Prices
NA
0
FDF
0
Data Compilation #PharmaFlow
0
Stock Recap #PipelineProspector
0
Weekly News Recap #Phispers
1. (1s,9s)-1-amino-9-ethyl-5-fluoro-2,3-dihydro-9-hydroxy-4-methyl-1h,12h-benzo(de)pyrano(3',4'-6,7)indolizino(1,2-b)quinoline-10,13(9h,15h)dione Methanesulfonate
2. Dx 8951
3. Dx 8951f
4. Dx-8951
5. Dx-8951a
6. Dx-8951f
7. Exatecan Mesilate Hydrate
8. Exatecan Mesylate
9. Exatecan Methanesulfonate Dihydrate
1. 171335-80-1
2. Exatecan [inn]
3. Dx-8951f
4. Oc71pp0f89
5. Dx-8951
6. (1s,9s)-1-amino-9-ethyl-5-fluoro-1,2,3,9,12,15-hexahydro-9-hydroxy-4-methyl-10h,13h-benzo(de)pyrano(3',4':6,7)indolizino(1,2-b)quinoline-10,13-dione
7. Dx 8951
8. Unii-oc71pp0f89
9. Exatecan-mesylate
10. (1s,9s)-1-amino-9-ethyl-5-fluoro-1,2,3,9,12,15-hexahydro-9-hydroxy-4-methyl-10h,13h-benzo[de]pyrano[3',4':6,7]indolizino[1,2-b]quinoline-10,13-dione
11. Exatecan [mi]
12. Exatecan [who-dd]
13. Schembl2512959
14. Chembl1614650
15. Dtxsid60169061
16. Chebi:135709
17. Ex-a2683
18. Zinc3800855
19. Nsc829066
20. Akos005146469
21. At33978
22. Bcp9000674
23. Db12185
24. Nsc-829066
25. 10h,13h-benzo(de)pyrano(3',4':6,7)indolizino(1,2-b)quinoline-10,13-dione, 1-amino-9-ethyl-5-fluoro-1,2,3,9,12,15-hexahydro-9-hydroxy-4-methyl-, (1s,9s)-
26. 10h,13h-benzo(de)pyrano(3',4':6,7)indolizino(1,2-b)quinoline-10,13-dione, 1-amino-9-ethyl-5-fluoro-1,2,3,9,12,15-hexahydro-9-hydroxy-4-methyl-, (1s-trans)-
27. Ac-32495
28. Bp-27996
29. Hy-13631
30. Db-064817
31. Dx8951;dx 8951;dx-8951
32. 335e801
33. J-521361
34. Q5419343
35. (10s,23s)-23-amino-10-ethyl-18-fluoro-10-hydroxy-19-methyl-8-oxa-4,15-diazahexacyclo[14.7.1.02,14.04,13.06,11.020,24]tetracosa-1,6(11),12,14,16,18,20(24)-heptaene-5,9-dione
Molecular Weight | 435.4 g/mol |
---|---|
Molecular Formula | C24H22FN3O4 |
XLogP3 | 0.4 |
Hydrogen Bond Donor Count | 2 |
Hydrogen Bond Acceptor Count | 7 |
Rotatable Bond Count | 1 |
Exact Mass | 435.15943435 g/mol |
Monoisotopic Mass | 435.15943435 g/mol |
Topological Polar Surface Area | 106 Ų |
Heavy Atom Count | 32 |
Formal Charge | 0 |
Complexity | 950 |
Isotope Atom Count | 0 |
Defined Atom Stereocenter Count | 2 |
Undefined Atom Stereocenter Count | 0 |
Defined Bond Stereocenter Count | 0 |
Undefined Bond Stereocenter Count | 0 |
Covalently Bonded Unit Count | 1 |
Topoisomerase I Inhibitors
Compounds that inhibit the activity of DNA TOPOISOMERASE I. (See all compounds classified as Topoisomerase I Inhibitors.)
Cohance Lifesciences, offers full range of CDMO services for small molecule APIs, intermediates, ADCs, Pellets and Formulations.
Shanghai Minbiotech is the leading producer of biopharmaceuticals and a variety of high-end generic & innovative drugs.
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 37905
Submission : 2022-12-30
Status : Active
Type : II
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 37610
Submission : 2023-06-07
Status : Active
Type : II
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 37214
Submission : 2022-06-24
Status : Active
Type : II
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 36708
Submission : 2022-01-20
Status : Active
Type : II
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 36614
Submission : 2022-01-03
Status : Active
Type : II
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 41144
Submission : 2025-01-05
Status : Active
Type : II
USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others
USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 37906
Submission : 2023-07-31
Status : Active
Type : II
Portfolio PDF
Product Web Link
Virtual Booth
Digital Content
Website
Corporate PDF
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 37214
Submission : 2022-06-24
Status : Active
Type : II
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 36708
Submission : 2022-01-20
Status : Active
Type : II
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 37905
Submission : 2022-12-30
Status : Active
Type : II
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 41144
Submission : 2025-01-05
Status : Active
Type : II
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 37610
Submission : 2023-06-07
Status : Active
Type : II
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 36614
Submission : 2022-01-03
Status : Active
Type : II
USDMF
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 37906
Submission : 2023-07-31
Status : Active
Type : II
Portfolio PDF
Product Web Link
Virtual Booth
Digital Content
Website
Corporate PDF
USDMF
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 40540
Submission : 2024-11-06
Status : Active
Type : II
Portfolio PDF
Product Web Link
Virtual Booth
Digital Content
Website
Corporate PDF
Cohance Lifesciences, offers full range of CDMO services for small molecule APIs, intermediates, ADCs, Pellets and Formulations.
About the Company : Cohance Lifesciences is a leading CDMO and API platform, offering products and services across all phases of a molecule’s lifecycle from development to commercialzation. With our...
Shanghai Minbiotech is the leading producer of biopharmaceuticals and a variety of high-end generic & innovative drugs.
About the Company : Headquartered in Fengxian District, Shanghai Minbiotech Co., Ltd. is a company specializing in the R&D and production of advanced pharmaceutical intermediates and biological API...
About the Company : JIN DUN Medical Research Institute is affiliated to Shanghai JIN DUN Industrial Co., Ltd., headquartered in Shanghai, adjacent to Hongqiao High-speed Railway Station and Hongqiao I...
About the Company : Zhejiang Huida Biotech Co., Ltd. is located in Hangzhou, Zhejiang Province. It was established in 2020 and is a holding subsidiary of Huadong Medicine Co., Ltd. The company focu...
API/FDF Prices: Book a Demo to explore the features and consider upgrading later
API Imports and Exports
Importing Country | Total Quantity (KGS) |
Average Price (USD/KGS) |
Number of Transactions |
---|
Upgrade, download data, analyse, strategize, subscribe with us
Details:
Dr. DeCillis will lead the development of the first-in-human study of Cybrexa’s lead program, CBX-12 (alphalexTM-exatecan), and early and late stage clinical programs for the Cybrexa portfolio.
Lead Product(s): Exatecan
Therapeutic Area: Oncology Brand Name: Undisclosed
Study Phase: PreclinicalProduct Type: Other Small Molecule
Sponsor: Inapplicable
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable March 31, 2020
Lead Product(s) : Exatecan
Therapeutic Area : Oncology
Highest Development Status : Preclinical
Partner/Sponsor/Collaborator : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Dr. DeCillis will lead the development of the first-in-human study of Cybrexa’s lead program, CBX-12 (alphalexTM-exatecan), and early and late stage clinical programs for the Cybrexa portfolio.
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
March 31, 2020
CAS Number : 110351-94-5
End Use API : Exatecan
About The Company : Hangzhou Hairui Chemical Co., Ltd. is located in the Zhongheng Century Science and Technology Park in Hangzhou, Zhejiang. It is an excellent manufacturer of org...
CAS Number : 110351-94-5
End Use API : Exatecan
About The Company : Established in 2011 and situated in Hangzhou, Zhejiang, China, Hangzhou Longshine Bio-Tech CO., Ltd is dedicated to providing services for pharmaceutical and ch...
CAS Number : 110351-94-5
End Use API : Exatecan
About The Company : Hefei Hirisun Pharmatech Co., Ltd located in Hefei China, is a leading and developing Biotech enterprise, specialize in providing fine chemical, novel biochemic...
CAS Number : 110351-94-5
End Use API : Exatecan
About The Company : Gruechem, established in 2011, is dedicated to the custom synthesis, and custom-manufacturing of building blocks, core skeletons, and molecular frameworks, whic...
Market Place
Reply
30 Aug 2024
Reply
26 Sep 2022
ABOUT THIS PAGE
68
PharmaCompass offers a list of Exatecan API manufacturers, exporters & distributors, which can be sorted by GMP, USDMF, JDMF, KDMF, CEP (COS), WC, Price,and more, enabling you to easily find the right Exatecan manufacturer or Exatecan supplier for your needs.
Send us enquiries for free, and we will assist you in establishing a direct connection with your preferred Exatecan manufacturer or Exatecan supplier.
PharmaCompass also assists you with knowing the Exatecan API Price utilized in the formulation of products. Exatecan API Price is not always fixed or binding as the Exatecan Price is obtained through a variety of data sources. The Exatecan Price can also vary due to multiple factors, including market conditions, regulatory modifications, or negotiated pricing deals.
A Exatecan Mesylate manufacturer is defined as any person or entity involved in the manufacture, preparation, processing, compounding or propagation of Exatecan Mesylate, including repackagers and relabelers. The FDA regulates Exatecan Mesylate manufacturers to ensure that their products comply with relevant laws and regulations and are safe and effective to use. Exatecan Mesylate API Manufacturers are required to adhere to Good Manufacturing Practices (GMP) to ensure that their products are consistently manufactured to meet established quality criteria.
click here to find a list of Exatecan Mesylate manufacturers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PhamaCompass.
A Exatecan Mesylate supplier is an individual or a company that provides Exatecan Mesylate active pharmaceutical ingredient (API) or Exatecan Mesylate finished formulations upon request. The Exatecan Mesylate suppliers may include Exatecan Mesylate API manufacturers, exporters, distributors and traders.
click here to find a list of Exatecan Mesylate suppliers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PharmaCompass.
A Exatecan Mesylate DMF (Drug Master File) is a document detailing the whole manufacturing process of Exatecan Mesylate active pharmaceutical ingredient (API) in detail. Different forms of Exatecan Mesylate DMFs exist exist since differing nations have different regulations, such as Exatecan Mesylate USDMF, ASMF (EDMF), JDMF, CDMF, etc.
A Exatecan Mesylate DMF submitted to regulatory agencies in the US is known as a USDMF. Exatecan Mesylate USDMF includes data on Exatecan Mesylate's chemical properties, information on the facilities and procedures used, and details about packaging and storage. The Exatecan Mesylate USDMF is kept confidential to protect the manufacturer’s intellectual property.
click here to find a list of Exatecan Mesylate suppliers with USDMF on PharmaCompass.
Exatecan Mesylate Active pharmaceutical ingredient (API) is produced in GMP-certified manufacturing facility.
GMP stands for Good Manufacturing Practices, which is a system used in the pharmaceutical industry to make sure that goods are regularly produced and monitored in accordance with quality standards. The FDA’s current Good Manufacturing Practices requirements are referred to as cGMP or current GMP which indicates that the company follows the most recent GMP specifications. The World Health Organization (WHO) has its own set of GMP guidelines, called the WHO GMP. Different countries can also set their own guidelines for GMP like China (Chinese GMP) or the EU (EU GMP).
PharmaCompass offers a list of Exatecan Mesylate GMP manufacturers, exporters & distributors, which can be sorted by USDMF, JDMF, KDMF, CEP (COS), WC, API price, and more, enabling you to easily find the right Exatecan Mesylate GMP manufacturer or Exatecan Mesylate GMP API supplier for your needs.
A Exatecan Mesylate CoA (Certificate of Analysis) is a formal document that attests to Exatecan Mesylate's compliance with Exatecan Mesylate specifications and serves as a tool for batch-level quality control.
Exatecan Mesylate CoA mostly includes findings from lab analyses of a specific batch. For each Exatecan Mesylate CoA document that a company creates, the USFDA specifies specific requirements, such as supplier information, material identification, transportation data, evidence of conformity and signature data.
Exatecan Mesylate may be tested according to a variety of international standards, such as European Pharmacopoeia (Exatecan Mesylate EP), Exatecan Mesylate JP (Japanese Pharmacopeia) and the US Pharmacopoeia (Exatecan Mesylate USP).